山东威高血液净化制品股份有限公司 第二届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603014 证券简称：威高血净 公告编号：2025-006 一、监事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届监 事会第八次会议于 2025 年 5 月 27 日以现场和通讯相结合的方式在公司会议室召开。 本次会议由监事会主席宋大鹏召集并主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法 规和《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过了《关于调整募集资金投资项目拟投入募集资金金额、内部投 资结构的议案》 公司监事会认为，本次对募投项目拟使用募集资金金额及内部投资结构的调整 是基于公司实际募集资金情况，并根据自身业务战略布局及实际经营发展需要所做 出的审慎决策。本次调整不存在改变或变相改变募集资金投向的情形，符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-005 山东威高血液净化制品股份有限公司 第二届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十一次会议于 2025 年 5 月 27 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 5 月 16 日通过通讯方式送达全体董事。本次会议由董事长 宋修山召集并主持，会议应出席董事 9 人，实际出席董事 9 人，公司监事和高级管 理人员列席了会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司 法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过了《关于调整募集资金投资项目拟投入募集资金金额、内部投 资结构的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司关于调整募集 ...

威高血净：使用募集资金置换2.77亿元自筹资金 金十数据5月27日讯，威高血净公告，公司于2025年5月27日召开董事会和监事会，审议通过使用募集资 金置换预先投入募投项目及已支付发行费用的自筹资金。置换金额包括募投项目2.4亿元和发行费用 3663.52万元，合计2.77亿元。募集资金总额为10.9亿元，净额为9.78亿元，募投项目包括威高血液净化 智能化生产建设项目、透析器（赣州）生产建设项目等。募集资金已存放于专项账户，公司将进行等额 置换。 ...

（文章来源：证券时报网） 佳合科技 | 301501 | 恒鑫生活 | 78.88 | 35.12 | -6.79 | | --- | --- | --- | --- | --- | | 603014 | C威高 | 37.11 | 34.65 | -4.53 | | 688755 | C汉邦 | 46.83 | 34.54 | -4.82 | | 920068 | 天工股份 | 20.90 | 33.73 | -7.11 | | 870299 | 灿能电力 | 23.78 | 33.65 | -5.63 | | 001206 | 依依股份 | 24.35 | 33.46 | 6.15 | | 300040 | 九洲集团 | 8.10 | 33.26 | -4.48 | | 301488 | 豪恩汽电 | 76.00 | 32.75 | -2.25 | | 600610 | 中毅达 | 15.79 | 32.63 | -5.11 | | 300703 | 创源股份 | 18.58 | 32.49 | -2.31 | | 837023 | 芭薇股份 | 29.28 | 32.19 | -4.38 | | 301 ...

Group 1 - C Weigao (603014) saw a first-day increase of 56.26%, with a turnover rate of 69.71% and a transaction volume of 1.15 billion yuan [2] - The stock had a net inflow of 178 million yuan from major funds on its first trading day, with large orders contributing 130 million yuan [3] - The stock's first-day financing amount was 39.74 million yuan, accounting for 3.46% of the total trading volume, with a latest financing balance of 34.33 million yuan, representing 2.18% of the circulating market value [2][3] Group 2 - C Weigao specializes in the research, production, and sales of blood purification medical products [3] - On the first trading day, the top five trading departments on the dragon and tiger list had a total transaction of 175 million yuan, with a net selling of 10.46 million yuan [3] - The financing balance for C Weigao on its first day was 34.33 million yuan, with no short selling balance recorded [3]

Policy Developments - Abbott Molecular Inc. has initiated a recall of its automated real-time fluorescent nucleic acid amplification analysis system due to design defects [1] - Other companies including Ortho Clinical Diagnostics, Leica Biosystems, Beckman Coulter, and Aesculap have also recalled products due to various issues such as potential bias in reportable range, incorrect labeling, cross-contamination, and rising complaint trends [1] Drug and Device Approvals - Jianyou Co., Ltd. has received FDA approval for the production site transfer of its Idarubicin Hydrochloride Injection in multiple dosages [2] - Xinhua Pharmaceutical has been granted approval for the listing of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [3] Capital Market Activities - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan, will be listed on the New Third Board starting May 20, 2025 [4] - Chuangxin International has completed nearly 100 million RMB in Series B financing led by Yueke Fund and Zhongshan Haochuang Fund [5] Industry Events - Kanghui Pharmaceutical has won a first-instance judgment in a lawsuit against Kelewei Biopharmaceuticals regarding equity repurchase, requiring Kelewei to pay 2 million RMB in deposit and 35.994 million RMB in repurchase funds [6] - Weigao Blood Purification Products Co., Ltd. has officially listed on the Shanghai Stock Exchange, raising approximately 1.09 billion RMB through its IPO [7] Public Sentiment Alerts - Sanleaf Bio has changed its accounting firm due to disagreements over audit fees [8] Management Changes - Dize Pharmaceutical's executives plan to reduce their shareholdings due to personal financial needs, with specific amounts detailed for each individual [9][10] - Jia Ying Pharmaceutical's CFO has resigned for personal reasons and will no longer hold any position within the company [11]

Core Insights - Shandong Weigao Blood Purification Products Co., Ltd. officially listed on the Shanghai Stock Exchange on May 19, marking a new chapter in its capital market journey [1] - The company has been dedicated to meeting the blood purification needs of global kidney disease patients for over 20 years, focusing on hemodialysis and peritoneal dialysis [1] Market Position - As of 2023, Weigao Blood Purification holds the leading market shares in China for hemodialysis devices and blood dialysis tubing, with shares of 32.5% and 31.8% respectively [2] - The company ranks second in the market for hemodialysis machines with a 24.6% market share, closely following Fresenius Medical [2] Financial Performance - Weigao Blood Purification reported revenues of 3.426 billion yuan, 3.532 billion yuan, and 3.604 billion yuan for the years 2022, 2023, and 2024 respectively [2] - The net profits attributable to shareholders were 315 million yuan, 442 million yuan, and 449 million yuan for the same years, indicating strong profitability and market resilience [2] Technological Advancements - The company is actively engaged in the research and development of core technologies related to biomedical membranes, significantly improving solute clearance rates by over 15% and reducing allergy risks for patients [3] - Weigao's technological breakthroughs have prompted international competitors to reassess their development directions, accelerating global advancements in blood purification technology [3] Investment and Growth Strategy - The IPO proceeds will primarily fund projects in intelligent production, the establishment of a hemodialysis device production base, R&D center development, and digital information technology platform construction [4] - Future R&D investments will focus on next-generation hemodialysis devices, innovative production equipment, and fully automated manufacturing equipment [5] Market Expansion - The company plans to enhance cooperation with grassroots medical institutions to increase product coverage in lower-tier cities and rural areas, capitalizing on the growing demand for blood purification equipment [5] - Weigao has been expanding its international presence since 2016, with a notable market share in Southeast Asia, particularly in Indonesia [5] Industry Outlook - The blood purification industry in China is poised for significant growth due to an aging population, rising chronic kidney disease prevalence, and improved treatment penetration rates [5] - The company aims to leverage capital market opportunities to enhance brand influence and contribute to the health of chronic kidney disease patients in China [5]

- The report tracks the recent performance of the offline IPO market for the STAR Market, ChiNext, and the Main Board, assuming all stocks are hit and sold at the market average price on the first day of listing, ignoring the lock-up period restrictions [1][11] - Since 2025 until 2025/5/16, the IPO yield for a Class A 2 billion account is 1.32%, and for a Class B 2 billion account is 1.15%; for a Class A 10 billion account, the IPO yield is 0.30%, and for a Class B 10 billion account, the IPO yield is 0.27% [1][11] - The median number of valid quotation accounts for recent 20 new stocks is tracked, with the number of valid quotation accounts for Class A STAR Market new stocks around 3051, and for Class B around 1784; for Class A ChiNext new stocks around 3414, and for Class B around 2056; for Class A Main Board stocks around 3493, and for Class B around 2376 [2][23] - The average first-day increase for STAR Market stocks is 198.41%, and for ChiNext stocks is 227.46% [1][16] - The report measures the theoretical IPO yield for different scale accounts, assuming all stocks are hit and sold at the market average price on the first day of listing, ignoring the lock-up period restrictions [1][11] - The report lists the IPO results for recent new stocks, including the issuance price, issuance P/E ratio, industry P/E ratio, number of new shares issued, and the actual fundraising amount [25][26] - The report provides a calendar of recent IPOs, including the status of stocks waiting for inquiry, waiting for issuance price announcement, waiting for subscription, and waiting for listing [27][28][29] - The report calculates the full subscription yield for each stock, using the average winning rate of Class A institutions to estimate the yield when fully subscribed [35][37] - The report lists the monthly IPO yield and IPO yield rate for different scale Class A accounts, assuming all stock quotations are included, with a 90% fund utilization efficiency [42][43][44][45][46] - The report lists the monthly IPO yield and IPO yield rate for different scale Class B accounts, assuming all stock quotations are included, with a 90% fund utilization efficiency [47][48][49][50][51]

Core Viewpoint - Weigao Blood Purification officially listed on the Shanghai Stock Exchange on May 19, 2023, raising approximately 1.09 billion yuan with a closing price of 41.41 yuan per share, a 56.26% increase from the issue price [1][2]. Group 1: Financial Performance - Weigao Blood Purification's revenue for 2024 is projected to be 3.604 billion yuan, a 2.04% increase from 2023 [3]. - The company reported a net profit of 449 million yuan for 2024, up 1.58% from 2023 [3]. - The average selling price of blood purification products has been declining, with the average factory price of blood purification devices dropping by 16% and 11% in 2024 [7][8]. Group 2: Market Position and Competition - The blood purification industry in China is facing intense competition, with international giants like Fresenius and Baxter dominating the market [1][4]. - Weigao Blood Purification holds the largest market share in the domestic blood purification device sector, with 32.5% for blood purification devices and 31.8% for blood purification tubing [5][6]. - The company’s blood purification machine revenue has been declining due to procurement delays, with revenues dropping from 660 million yuan in 2022 to 619 million yuan in 2024 [5][6]. Group 3: Business Strategy and Challenges - The funds raised from the IPO will be used for the construction of intelligent production facilities and the development of new high-performance consumables [1]. - The company faces challenges from reliance on joint ventures for key products, which could impact overall performance if partnerships deteriorate [7]. - The implementation of volume-based procurement policies is pressuring prices and profit margins, with projected declines in gross profit margins [8][12]. Group 4: R&D and Sales Dynamics - R&D expenses for Weigao Blood Purification are relatively low compared to sales expenses, with R&D accounting for only 4.57% of revenue in 2024 [9][10]. - The company has faced scrutiny regarding high sales expenses, which are approximately 20% of revenue, higher than comparable companies [10]. - The need for a balance between high R&D investment and compliance with regulations is a significant challenge for the company and the industry as a whole [12].

Core Viewpoint - The blood purification market in China is experiencing significant growth, driven by an increasing number of patients with uremia and an aging population, with a projected annual growth rate of 15% [2] Group 1: Market Overview - The blood purification market in China is expected to grow from 11.6 billion in 2019 to 21.1 billion by 2025, and reach 51.515 billion by 2030, indicating substantial growth potential [2] - The company Weigao Blood Purification holds a leading market share in blood dialysis devices, with 32.5% in blood dialysis filters and 31.8% in blood dialysis tubing, and a second position in dialysis machines with a 24.6% market share [2] Group 2: Financial Performance - Weigao Blood Purification's revenue from 2022 to 2024 is projected to be 3.426 billion, 3.532 billion, and 3.604 billion respectively, with net profits of 315 million, 442 million, and 449 million, demonstrating stable growth [3] - The net profit growth in 2023 was 40.36%, followed by a slight increase of 1.65% in 2024, aligning with the industry's strategy of "volume for price" under the background of centralized procurement [3] Group 3: Company Overview - Weigao Blood Purification is the fourth listed company under Weigao Group, focusing on the research, production, and sales of blood purification medical products, covering the entire industry chain of blood dialysis and peritoneal dialysis [5] - The company collaborates with international firms like Nikkiso and Terumo to enhance the technology level of high-end products [5] Group 4: Product Line Development - The company launched its first self-developed blood dialysis filter in 2005, breaking the overseas monopoly, and has since introduced various innovative products, including the first polysulfone membrane dialysis filter in 2008 and the high-flux HF series in 2013 [6][8] - Blood dialysis tubing sales increased from 30.06 million sets in 2022 to 39 million sets in 2024, with revenue rising from 414 million to 495 million, marking a growth of approximately 29.74% [9]